<DOC>
	<DOCNO>NCT00002653</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know combination chemotherapy regimen effective treat old patient multiple myeloma . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy without cyclophosphamide prednisone treat old patient multiple myeloma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Cyclophosphamide Prednisone Treating Older Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy doxorubicin , carmustine , cyclophosphamide , melphalan ( ABCM ) without oral cyclophosphamide prednisone induction first plateau phase elderly patient previously untreated multiple myeloma . OUTLINE : This randomize , multicenter study . Patients stratify accord center . Patients receive doxorubicin IV follow immediately carmustine IV 1-2 hour day 1 oral melphalan ( L-PAM ) oral cyclophosphamide ( CTX ) day 22-25 ( ABCM ) . Treatment continue every 6 week 3 course absence disease progression unacceptable toxicity . Patients whose blood count recover within 6 week begin L-PAM CTX course 3 randomize 1 2 treatment arm . Patients whose blood count fail recover within 6 week begin L-PAM CTX course 3 assigned arm II . - Arm I : Patients continue ABCM maximum 12 course absence plateau phase completion least 4 course , disease progression , unacceptable toxicity . - Arm II : Patients receive oral cyclophosphamide weekly oral prednisone every day . Treatment continue every 6 week absence plateau phase completion 3 course ABCM plus minimum 8 week arm II le 3 course ABCM plus 6 month arm II , disease progression , unacceptable toxicity . Patients arm bone pain failure respond chemotherapy may undergo minimal radiotherapy . Patients achieve plateau phase may enter MRC trial interferon alfa-2b . Patients follow every 3 month . PROJECTED ACCRUAL : A total 1,000 patient accrue study within approximately 5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma , define least 2 follow condition : Neoplastic cell infiltrate and/or microplasmacytomas bone marrow section smear Plasma cell infiltrate great 20 % marrow nucleated cell , le 20 % , objective evidence monoclonality plasma cell require Paraprotein blood urine Definite lytic bone lesion ( osteoporosis ) Nonsecretory disease allow presence 1 follow condition : Microplasmacytomas Monoclonal plasmacytosis immunoglobulin lightchain expression cytoplasm No equivocal myelomatosis , define follow criterion : Minimal symptom attributable myelomatosis Pretransfusion hemoglobin great 10 g/dL Posthydration creatinine le 1.47 mg/dL No osteolytic lesion except minimal lesion threaten pathological fracture associate pain Plasma cell less 30 % marrow nucleated cell marrow show normal hematopoietic activity Serum beta2 microglobulin le 4 mg/L Less 1 g free lightchain excretion per 1 g creatinine No objective factor indicate progressive myelomatosis PATIENT CHARACTERISTICS : Age : 65 74 If 65 , high priority give protocol MRCLEUKMYELVII unless entry study would appropriate Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Neutrophil count least 1,300/mm^3 Platelet count least 75,000/mm^3 Hepatic : Not specify Renal : See Disease Characteristics Other : Ability tolerate fluid intake least 3 L/day begin least 2 day study entry Afebrile free infection No contraindication therapy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Prior concurrent prednisolone 30 mg/m2/day less ( equivalent dos corticosteroid ) relief fluidunresponsive hypercalcemia allow Radiotherapy : Prior concurrent minimal local radiotherapy relieve persistent bone pain cord compression allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>